ACTINIUM PHARMACEUTICALS overview
ACTINIUM PHARMACEUTICALS
> News
PR Newswire published a news.
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA Trial
•
•
PR Newswire •
Stocks •
More ACTINIUM PHARMACEUTICALS news...
Thank you
Chart
ACTINIUM PHARMACEUTICALS
> News
PR Newswire published a news.
Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
•
•
PR Newswire •
Stocks •
More ACTINIUM PHARMACEUTICALS news...
Thank you
Chart
ACTINIUM PHARMACEUTICALS
> Analyses
Thank you
Reply
Chart
Londinia
has published a new analysis.
- 0
- 75537
- 15128
- 0
Timeframe : Daily - Simple chart
Status : INVALID
The strong short-term decline in ACTINIUM PHARMACEUTICALS calls into question the currently slightly bullish basic trend. A trend reversal is likely. As long as the price remains below the resistance
ACTINIUM PHARMACEUTICALS
> News
PR Newswire published a news.
Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting
•
•
PR Newswire •
Stocks •
More ACTINIUM PHARMACEUTICALS news...
Thank you
Chart
Statistics
- Analyses : 21
- Followers : 2